beta-Amyrin palmitate
CAS No. 5973/6/8
beta-Amyrin palmitate ( —— )
产品货号. M31009 CAS No. 5973/6/8
Beta-Amyrin palmitate may release norepinephrine from newly synthesized pools, and thus, it may activate noradrenergic activity.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥2822 | 有现货 |
|
50MG | 获取报价 | 有现货 |
|
100MG | 获取报价 | 有现货 |
|
5MG | ¥2822 | 有现货 |
|
50MG | 获取报价 | 有现货 |
|
100MG | 获取报价 | 有现货 |
|
生物学信息
-
产品名称beta-Amyrin palmitate
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Beta-Amyrin palmitate may release norepinephrine from newly synthesized pools, and thus, it may activate noradrenergic activity.
-
产品描述Beta-Amyrin palmitate may release norepinephrine from newly synthesized pools, and thus, it may activate noradrenergic activity. Beta-Amyrin palmitate, like mianserin and imipramine, reduces the duration of immobility of mice significantly in a dose-dependent manner (5, 10 and 20 mg kg-1); (1)Beta-Amyrin palmitate or mianserin elicits a dose-related reduction in locomotor activity of mice and antagonizes locomotor stimulation induced by methamphetamine, imipramine increases locomotor activity and potentiates methamphetamine-induced hyperactivity; (2)Beta-Amyrin palmitate shows no effect on reserpine-induced hypothermia, whilst mianserin (10 mg kg-1) and imipramine (10 and 20 mg kg-1) antagonizes the reserpine-induced effect; (3)Beta-amyrin palmitate has similar properties in some respects to mianserin and might possess a sedative action.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体LDL | HMG-CoA Reductase | Adrenergic Receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number5973/6/8
-
分子量665.1
-
分子式C46H80O2
-
纯度>98% (HPLC)
-
溶解度DMSO, Pyridine, Methanol, Ethanol, etc.
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.J Pharm Pharmacol. 1993 Jun;45(6):545-50.
产品手册
关联产品
-
2-(Acetylamino)-3-ph...
2-(Acetylamino)-3-phenyl-2-propenoic acid is a natural product for research related to life sciences.
-
Prolactin Releasing ...
Prolactin Releasing Peptide (1-31), human is a high affinity GPR10 ligand that cause the release of the prolactin.
-
ICCB280
ICCB280 was capable of inducing differentiation and apoptosis of ATRA-resistant patient blasts strongly signify that the activity of this compound can overcome resistance to other current therapies for AML with an unfavorable prognosis.